Stereotactic Ablative Radiation for Systemic Therapy-naive Oligometastatic Kidney Cancer.

ABSTRACT:

Background

Evidence-based guidelines for the management of systemic therapy-naïve oligometastatic renal cell carcinoma (RCC) are lacking.

Objective

To evaluate the potential of stereotactic ablative radiotherapy (SAbR) to provide longitudinal disease control while preserving quality of life (QOL) in patients with systemic therapy-naïve oligometastatic RCC.

Design, setting, and participants

RCC patients with three or fewer extracranial metastases were eligible. SAbR was administered longitudinally to all upfront and, as applicable, subsequent metastases.

Outcome measurements and statistical analysis

This prospective phase II single-arm trial was powered to achieve a primary objective of freedom from systemic therapy for >1 yr in >60% of patients (using the Clopp

SUBMITTER: Hannan R 

PROVIDER: S-EPMC9988242 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature